Skip to main content
AddLife logo

AddLife — Investor Relations & Filings

Ticker · ALIF ISIN · SE0014401378 LEI · 5493005T3M7CD7XWE013 ST Wholesale and retail trade
Open in API
Filings indexed 294 across all filing types
Latest filing 2024-02-02 Earnings Release
Country SE Sweden
Listing ST ALIF

About AddLife

https://www.add.life/

AddLife is a life science group that operates through a decentralized model, acquiring and developing market-leading companies in niche segments. The group consists of numerous independent subsidiaries that provide specialized products, services, and advisory support primarily to the healthcare and research sectors. Its offerings encompass a broad range of instruments, equipment, consumables, and advanced solutions for diagnostics, medical technology, and biomedical research and laboratory analysis. AddLife's business strategy focuses on combining the strength and resources of a large enterprise with the entrepreneurial drive and agility of its subsidiaries, fostering growth and innovation while preserving the unique culture of each acquired company.

Recent filings

Filing Released Lang Actions
Earnings Release 2023
Earnings Release Classification · 100% confidence The document is titled "Bokslutskommuniké 1 januari – 31 december 2023" (Year-end report communication 1 January – 31 December 2023) and contains detailed financial figures for both the fourth quarter (3 months) and the full year (12 months) ending December 31, 2023. It includes key performance indicators like Net Sales, EBITA, Net Income, EPS, and Cash Flow, along with a CEO commentary and proposed dividend. This structure is characteristic of a comprehensive annual financial report release, which aligns best with the Annual Report (10-K) definition, although the language is Swedish. Since it covers the full fiscal year and provides detailed financial statements/summaries, it is classified as the primary annual report document type. FY 2023
2024-02-02 Swedish
Audit Report / Information 2023
Audit Report / Information Classification · 98% confidence The document contains detailed financial figures for a full year (1 January – 31 December 2023) and the fourth quarter, including Net sales, EBITA, Profit after tax, and Earnings per share. It features a CEO's commentary on performance, strategic measures, and a proposal for dividend distribution to the Annual General Meeting. The structure, comprehensive nature, and presentation of full-year financial results strongly indicate this is the company's primary annual financial report, which corresponds to the definition of a 10-K (Annual Report), even if the document itself is not explicitly labeled '10-K' in the provided text snippet. The length (over 80,000 characters) confirms it is a full report, not just a brief announcement (ruling out RPA/RNS). FY 2023
2024-02-02 English
AddLife continues its review of Homecare
Legal Proceedings Report Classification · 99% confidence The document announces a significant business decision: the planned closure of a subsidiary (Camanio) and the associated impairment loss of SEK 100 million to be reported in Q4 2023. It also mentions the discontinuation timeline (Q1 2024 to Q3 2024) and provides contact information and regulatory disclosure statements (EU Market Abuse Regulation). This content is a specific, material corporate event announcement that is not a full annual report (10-K), an earnings release (ER) focusing on broad results, or a management discussion (MDA). It relates to a significant change in operations and financial structure, specifically concerning asset impairment due to a strategic decision. While it impacts financials, it is primarily a strategic/operational update leading to an impairment charge. Given the options, this type of announcement detailing a major strategic restructuring and associated write-downs fits best under Capital/Financing Update (CAP) if it involves restructuring capital, or potentially Regulatory Filings (RNS) if it's a mandatory disclosure not covered elsewhere. However, since it details a major financial impact (impairment loss) resulting from a strategic decision (closure), and it is not a standard earnings report, it is most closely aligned with a significant corporate action update. Since there isn't a specific 'Restructuring/Impairment Notice' code, and it is a mandatory disclosure under MAR, RNS is the safest fallback. However, if we interpret the impairment and closure as a significant change in capital structure or financing activity related to winding down a segment, CAP might be considered. Given the nature of the announcement—a specific, material event disclosure required under MAR, rather than a general financial report—RNS (Regulatory Filings) is the most appropriate general category for mandatory, non-standard disclosures.
2024-01-08 English
AddLife fortsätter översynen av Homecare
Legal Proceedings Report Classification · 99% confidence The document is a short announcement dated January 8, 2024, from AddLife AB (publ). It details a strategic decision to initiate union negotiations for the planned divestment/winding down of a subsidiary (Camanio) and its associated development projects. It explicitly mentions a significant non-cash impairment charge (100 MSEK) to be recorded in Q4 2023 and outlines the timeline for the wind-down (Q1 2024 to Q3 2024). Crucially, the final paragraph states: "Denna information är sådan information som AddLife AB (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning..." (This information is such information that AddLife AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation...). This structure—a brief, mandatory disclosure concerning a significant corporate action (divestment/impairment) under MAR obligations—is characteristic of a general regulatory announcement, often categorized as Regulatory Filings (RNS) when it doesn't fit a more specific category like M&A (TAR) or Capital Change (CAP). Since it is an announcement of a corporate action/restructuring rather than a full financial report (10-K, IR) or a specific management discussion (MDA), RNS is the most appropriate general regulatory fallback.
2024-01-08 Swedish
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document details a change in shareholding percentage for a specific instrument (B class shares SE0014401378) held by SEB Investment Management AB in Issuer AddLife AB. It explicitly shows the 'Before the transaction' and 'After the transaction' share quantities and the resulting percentage of voting rights (10.00296% and 7.4693%). This structure—reporting personal or institutional transactions by insiders or major shareholders crossing notification thresholds—is characteristic of Director's Dealing (DIRS) or Major Shareholding Notification (MRQ). Since the document explicitly tracks the change in the number of shares held by a significant holder (SEB Investment Management AB) and the resulting percentage crossing a threshold (implied by the 'Limit for number of shares 10 %' header and the resulting percentage), it most closely aligns with a Major Shareholding Notification (MRQ). Director's Dealing (DIRS) usually refers specifically to directors/executives, whereas this is an investment management firm. The content is a direct notification of a holding change, not a general announcement of a report.
2023-11-22 English
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document details a change in shareholding and voting rights for a specific instrument (equity SE0014401378) held by Odin Forvaltning as in AddLife AB. It explicitly shows the 'Before the transaction' and 'After the transaction' quantities of shares and voting rights, including the resulting percentage change. This structure is characteristic of a notification regarding a change in significant share ownership, which aligns with the definition for Major Shareholding Notification (MRQ). It is not an earnings release, annual report, or a director's dealing (DIRS), as it concerns a major shareholder/holder, not necessarily a director.
2023-10-26 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.